Updating results

248 results for breast cancer Sort: Relevance | Date

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated March 2018

Early and locally advanced breast cancer

Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated March 2018

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

Evidence-based recommendations on familial (inherited) breast cancer and related risks for people with a family history of breast cancer

Clinical guideline Published June 2013 Last updated March 2017

Advanced breast cancer: diagnosis and treatment (CG81)

Evidence-based recommendations on diagnosing and treating advanced (stage 4) breast cancer (invasive adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated August 2017

Breast cancer

All NICE products on Breast cancer. Includes any guidance, advice, NICE Pathways and quality standards.

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Early and locally advanced breast cancer: diagnosis and treatment (CG80)

Evidence-based recommendations on diagnosing and treating early and locally advanced (stage 1 & 2) breast cancer (adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated March 2017

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Familial breast cancer

Everything NICE has said on assessing and managing familial breast cancer and related risks in people with a family history in an interactive flowchart

NICE Pathway Published October 2011 Last updated September 2017

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer

Technology appraisal guidance Published January 2018

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment

Interventional procedures guidance Published January 2012

Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

Evidence-based recommendations on paclitaxel (Taxol) for adjuvant treatment of early node-positive breast cancer

Technology appraisal guidance Published September 2006

Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

Evidence-based recommendations on docetaxel (Taxotere) for adjuvant treatment of early node-positive breast cancer

Technology appraisal guidance Published September 2006

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

Evidence-based recommendations on trastuzumab (Herceptin) for adjuvant treatment of early-stage HER2-positive breast cancer

Technology appraisal guidance Published August 2006

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

Evidence-based recommendations on hormonal therapies (anastrozole/exemestane/letrozole) as extra treatment for early oestrogen-receptor-positive breast cancer

Technology appraisal guidance Published November 2006

Interstitial laser therapy for breast cancer (IPG89)

Evidence-based recommendations on interstitial laser therapy for treating breast cancer

Interventional procedures guidance Published September 2004

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Evidence-based recommendations on fulvestrant (Faslodex) for untreated locally advanced or metastatic (secondary) oestrogen-receptor positive breast cancer in

Technology appraisal guidance Published January 2018

Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer (keyhole removal of breast tissue)

Interventional procedures guidance Published April 2009

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer

Interventional procedures guidance Published December 2005

Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

Evidence-based recommendations on brachytherapy as the only type of adjuvant radiotherapy for breast cancer after local excision

Interventional procedures guidance Published July 2008

Improving outcomes in breast cancer (CSG1)

Evidence-based recommendations on improving outcomes in breast cancer

Cancer service guideline Published August 2002

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

ES15: Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

MIB135: MammaTyper in vitro diagnostic test for determining breast cancer subtypes

Advice on the use of the MammaTyper in vitro diagnostic test for determining breast cancer subtypes to aid local decision-making

Medtech innovation briefing Published January 2018

MIB76: Axxent electronic brachytherapy system for early stage breast cancer

Advice on the use of the Axxent electronic brachytherapy system for treating early stage breast cancer to aid local decision-making

Medtech innovation briefing Published August 2016

MIB111: L-Dex U400 for lymphoedema after breast cancer treatment

Advice on the use of L-Dex U400 for lymphoedema (lymphedema) after breast cancer treatment to aid local decision-making

Medtech innovation briefing Published July 2017

MIB44: EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence

Advice on the use of the EndoPredict gene expression profiling assay for assessing the risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published November 2015

MIB27: The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence

Advice on the use of the Prosigna gene expression profiling assay for assessing long-term risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published March 2015

Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions to test for breast cancer

Interventional procedures guidance Published July 2009

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964]

In development [GID-TA10030] Expected publication date: 21 December 2016

Technology appraisal guidance In development

Pertuzumab for adjuvant treatment of early HER2-positive breast cancer (ID1192)

In development [GID-TA10184] Expected publication date: 24 October 2018

Technology appraisal guidance In development

Breast cancer mortality rates

Breast cancer mortality rates Subject(s): Cancer NICE identity code: CCG04

CCG indicator Published June 2016

Ribociclib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer [ID1318]

In development [GID-TA10285] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer ID1227

In development [GID-TA10262] Expected publication date: 20 February 2019

Technology appraisal guidance In development